{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:07:57Z","timestamp":1784196477070,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","endocrinologydiabetes.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["AACE Endocrinology and Diabetes"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.aed.2026.03.004","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T08:05:22Z","timestamp":1774425922000},"page":"611-616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evinacumab Treatment of Homozygous Familial Hypercholesterolemia Patients in a Real-World Setting: An Overview After the First Year of Therapy"],"prefix":"10.1016","volume":"13","author":[{"given":"Laura","family":"Volpi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilja","family":"Demuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Steinhagen-Thiessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Kassner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bobbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.aed.2026.03.004_bib1","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.amjcard.2008.07.035","article-title":"Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia","volume":"102","author":"Kolansky","year":"2008","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.aed.2026.03.004_bib2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.5543\/tkda.2014.09633","article-title":"Long-term follow-up in patients with homozygous familial hypercholesterolemia; 13-year experience of a university hospital lipid clinic","volume":"42","author":"Kay\u0131k\u00e7\u0131o\u011flu","year":"2014","journal-title":"Turk Kardiyol Dernegi Arsivi"},{"issue":"279","key":"10.1016\/j.aed.2026.03.004_bib3","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/oxfordjournals.qjmed.a068478","article-title":"Natural history and cardiac manifestations of homozygous familial hypercholesterolaemia","volume":"76","author":"Haitas","year":"1990","journal-title":"Q J Med"},{"issue":"2","key":"10.1016\/j.aed.2026.03.004_bib4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.aed.2026.03.004_bib5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.aed.2026.03.004_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ihj.2015.05.020","article-title":"LDL cholesterol, statins and PCSK 9 inhibitors","volume":"67","author":"Gupta","year":"2015","journal-title":"Indian Heart J"},{"issue":"25","key":"10.1016\/j.aed.2026.03.004_bib7","doi-asserted-by":"crossref","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000624","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.aed.2026.03.004_bib8","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026550","article-title":"Real-world effectiveness of PCSK9 inhibitors in reducing LDL-C in patients with familial hypercholesterolemia in Italy: a retrospective cohort study based on the AIFA monitoring registries","volume":"12","author":"Arca","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.aed.2026.03.004_bib9","first-page":"311","article-title":"Influence of the LDL-receptor genotype on Statin response in heterozygous familial hypercholesterolemia: insights from the Canadian FH registry","volume":"38","author":"Roy","year":"2022","journal-title":"Can J Cardiol"},{"issue":"10","key":"10.1016\/j.aed.2026.03.004_bib10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the international atherosclerosis society severe familial hypercholesterolemia panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.aed.2026.03.004_bib11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.atherosclerosis.2015.03.014","article-title":"The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia \u2013 a post-hoc analysis of a phase 3, single-arm, open-label trial","volume":"240","author":"Stefanutti","year":"2015","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.aed.2026.03.004_bib12","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.5551\/jat.RV17065","article-title":"Advancements in the treatment of homozygous familial hypercholesterolemia","volume":"29","author":"Bajaj","year":"2022","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"10.1016\/j.aed.2026.03.004_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/1744-9987.13716","article-title":"The scientific basis and future of lipoprotein apheresis","volume":"26","author":"Thompson","year":"2022","journal-title":"Ther Apher Dial"},{"issue":"8","key":"10.1016\/j.aed.2026.03.004_bib14","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.aed.2026.03.004_bib15","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.aed.2026.03.004_bib16","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.aed.2026.03.004_bib17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/jcm12010168","article-title":"Evinacumab, an ANGPTL3 inhibitor, in the treatment of dyslipidemia","volume":"12","author":"Sosnowska","year":"2022","journal-title":"J Clin Med"},{"issue":"16","key":"10.1016\/j.aed.2026.03.004_bib18","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.aed.2026.03.004_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13836","article-title":"Evinacumab: mechanism of action, clinical, and translational science","volume":"17","author":"Dingman","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.aed.2026.03.004_bib20","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.aed.2026.03.004_bib21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.aed.2026.03.004_bib22","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1016\/j.jacl.2024.05.006","article-title":"Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis","volume":"18","author":"Stefanutti","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"27","key":"10.1016\/j.aed.2026.03.004_bib23","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","article-title":"Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy","volume":"45","author":"Gaudet","year":"2024","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.aed.2026.03.004_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"}],"container-title":["AACE Endocrinology and Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915726000640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050915726000640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:37:08Z","timestamp":1784194628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050915726000640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S3050915726000640"],"URL":"https:\/\/doi.org\/10.1016\/j.aed.2026.03.004","relation":{},"ISSN":["3050-9157"],"issn-type":[{"value":"3050-9157","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evinacumab Treatment of Homozygous Familial Hypercholesterolemia Patients in a Real-World Setting: An Overview After the First Year of Therapy","name":"articletitle","label":"Article Title"},{"value":"AACE Endocrinology and Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aed.2026.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Association of Clinical Endocrinology.","name":"copyright","label":"Copyright"}]}}